

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-QSB/A
AMENDMENT NO. 1

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES ACT OF 1934

For the quarterly period ended NOVEMBER 30, 2007

Commission File Number 0-12305

NEW YORK 13-3044880

(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)

24 CARPENTER ROAD, CHESTER, NY 10918

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (845) 469-2042

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes (X) No ()

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Outstanding at November 30, 2007
-----	-----
Common stock, \$.01 par value	32,804,286 shares

EXPLANATORY NOTE

The Company files this Amendment No. 1 to Form 10-QSB for the quarter ended August 31, 2007 to provide the disclosures required by Item 307 and Item 308(c) of Regulation S-B. This disclosure is provided under ITEM 7. CONTROLS AND PROCEDURES.

REPRO-MED SYSTEMS, INC.
TABLE OF CONTENTS

PAGE

PART I

ITEM 1. Financial Statements

Balance Sheet (Unaudited) - November 30, 2007 and February 28, 2007 (Audited)	3
Statements of Operations (Unaudited) - for the three-months Ending November 30, 2007 and November 30, 2006	4
Statements of Cash Flow (Unaudited) - for the three months Ending November 30, 2007 and November 30, 2006	5
Notes to Unaudited Financial Statements	6

ITEM 2. Management's Discussion and Analysis of

PART II

ITEM 1. Legal Proceedings	13
ITEM 2. Changes in Securities	13
ITEM 3. Defaults Upon Senior Securities	13
ITEM 4. Submission of Matters to a Vote of Security Holders	14
ITEM 5. Other Information	14
ITEM 6. Exhibits and Reports on Form 8-K	14
ITEM 7. Internal Controls and Producers	14

2

<TABLE>

REPRO-MED SYSTEMS, INC.
BALANCE SHEETS
ASSETS

<CAPTION>

	NOVEMBER 30, 2007 (UNAUDITED)	FEBRUARY 28, 2007 (AUDITED)	
	<C>	<C>	
CURRENT ASSETS:			
Cash	\$ 75,026	\$ 99,421	
Accounts Receivable less allowance for doubtful accounts of \$25,045 and \$21,950 for November 30, 2007 and February 28 2007 respectively		286,951	214,446
Inventory	495,515	489,738	
Prepaid Expenses	29,824	10,310	
TOTAL CURRENT ASSETS		887,316	813,915
PROPERTY & EQUIPMENT, less accumulated depreciation of \$1,095,662 and \$1,066,329 for November 30, 2007 and February 28, 2007, respectively		212,932	220,515
OTHER ASSETS:			
Patents, net of accumulated amortization of \$81,224 and \$78,675 for November 30, 2007 and February 28, 2007 respectively		43,034	40,588
Goodwill,	8,609	8,609	
Security Deposits	28,156	54,802	
TOTAL OTHER ASSETS		79,799	103,999
TOTAL ASSETS	\$ 1,180,047	\$ 1,138,429	

LIABILITIES AND STOCKHOLDERS' (DEFICIT)

CURRENT LIABILITIES

Notes payable to related parties	\$ 88,036	\$ 71,274	
Accounts Payable	400,599	443,440	
Accrued Expenses	82,539	46,179	
Accrued Interest	50,361	44,565	
Current Portion of capital lease obligations	-	617	
Accrued Preferred stock dividends	48,000	44,000	
Accrued payroll and related taxes	4,860	9,408	
TOTAL CURRENT LIABILITIES		674,395	659,483

OTHER LIABILITIES

Deferred capital gain	252,916	269,776	
Long-term debt - notes payable	855,000	855,000	
TOTAL OTHER LIABILITIES	1,107,916	1,124,776	
TOTAL LIABILITIES	1,782,311	1,784,259	

STOCKHOLDERS' DEFICIT

Preferred Stock, 8% cumulative, liquidation value \$100,000, \$0.01 par value, 2,000,000 shares authorized, 10,000 shares issued and outstanding 2007 and 2006, respectively	100	100
Common Stock, \$0.01 par value, 50,000,000 shares authorized, 32,804,286 and 31,033,286 issued and outstanding at November 30, 2007 and February 28, 2007, respectively	328,043	310,333
Additional paid-in Capital	2,708,396	2,612,748
Accumulated deficit	(3,496,803)	(3,427,011)
	(460,264)	(503,830)
Less: Treasury Stock, 2,275,000 shares at cost at November 30, 2007 and February 28, 2007 respectively	(142,000)	(142,000)
Total Stockholders' Deficit	(602,264)	(645,830)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	\$ 1,180,047	\$ 1,138,429

See Accompanying Notes to Financial Statements

3

</TABLE>

<TABLE>

REPRO-MED SYSTEMS, INC.
STATEMENT OF OPERATIONS
UNAUDITED

<CAPTION>

	FOR THE THREE MONTHS ENDED			FOR THE NINE MONTHS ENDED	
	NOVEMBER 30,		NOVEMBER 30,		
	2007	2006	2007	2006	
	-----	-----	-----	-----	
<S>	<C>	<C>	<C>	<C>	
NET SALES	\$ 620,879	\$ 457,991	\$ 1,624,242	\$ 1,221,724	
COST AND EXPENSES					
Cost of goods Sold	226,248	200,702	615,770	495,702	
Selling, general and administrative	288,987	205,094	871,356	715,205	
Research and development	8,651	9,990	34,761	31,622	
Depreciation and amortization	16,186	16,820	48,248	51,916	
	-----	-----	-----	-----	
TOTAL COSTS AND EXPENSES	540,072	432,606	1,570,135	1,294,445	
	=====	=====	=====	=====	
NET OPERATING PROFIT (LOSS)	80,807	25,385	54,107	(72,721)	
OTHER INCOME/(EXPENSES)					
Interest Expense	(19,448)	(93,080)	(120,410)	(211,443)	
Interest and Other Income	-	-	512	54	
	-----	-----	-----	-----	
TOTAL OTHER INCOME/(EXPENSE)	(19,448)	(93,080)	(119,898)	(211,389)	
	-----	-----	-----	-----	
NET PROFIT (LOSS) BEFORE TAXES	61,359	(67,695)	(65,791)	(284,110)	
Provision for Income Taxes	-	-	-	-	
	-----	-----	-----	-----	
NET PROFIT (LOSS) AFTER TAXES	\$ 61,359	\$ (67,695)	\$ (65,791)	\$ (284,110)	
	=====	=====	=====	=====	
NET PROFIT (LOSS) PER COMMON SHARE	0.01	(0.01)	(0.01)	(0.01)	
	=====	=====	=====	=====	
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING			32,193,155	30,613,286	

See Accompanying Notes to Financial Statements

4

</TABLE>

<TABLE>

REPRO-MED SYSTEMS, INC.

STATEMENT OF CASH FLOWS
UNAUDITED

<CAPTION>

FOR THE NINE MONTHS ENDED
NOVEMBER 30,
2007 2006

<S>

<C>

<C>

CASH FLOWS FROM OPERATING ACTIVITIES

Net Loss	\$(65,791)	\$(284,110)	
Adjustments to reconcile net loss to net cash used in operating activities:			
Stock based Compensation to obtain loan financing	75,840	159,390	
Stock Options to employee's and directors	37,518	-	
Depreciation and amortization	48,248	52,053	
Deferred capital gain - building lease	(16,860)	(16,860)	
Changes in operating assets and liabilities:			
(Increase) decrease in accounts receivable	(72,505)	(46,611)	
(Increase) decrease in inventory	(5,777)	(54,934)	
(Increase) decrease in prepaid expense	(19,514)	(4,428)	
Increase (decrease) in accounts payable	(42,842)	82,472	
Increase (decrease) in preferred stock dividend	4,000	-	
Increase (decrease) in accrued payroll and related taxes	(4,547)	-	
Increase (decrease) in accrued expense	36,360	(5,536)	
Increase (decrease) in accrued interest	5,795	-	
NET CASH USED IN OPERATING ACTIVITIES	(20,075)	(118,564)	
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property and equipment	(36,851)	(4,590)	
Additional patent costs	(6,260)	-	
Security Deposits	26,646	-	
NET CASH USED IN INVESTING ACTIVITIES	(16,465)	(4,590)	
CASH FLOWS FROM FINANCING ACTIVITIES			
Repayment of Bank Loan	-	(198,553)	
Preferred stock dividends	(4,000)	-	
Proceeds from note payable to related party	16,762	395,395	
Payments on capitalized lease obligations	(617)	(6,990)	
NET CASH PROVIDED BY FINANCING ACTIVITIES	12,145	189,852	
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(24,395)	66,698	
CASH AND CASH EQUIVALENTS-BEGINNING OF YEAR	99,421	26,753	
CASH AND CASH EQUIVALENTS-END OF YEAR	\$ 75,026	93,451	
Cash paid during the year for:			
Interest	14,698	52,053	

See Accompanying Notes to Financial Statements

5

</TABLE>

REPRO-MED SYSTEMS, INC.
NOTES TO THE FINANCIAL STATEMENTS
UN-AUDITED

BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and with instructions to Form 10-QSB. Accordingly, they do not include all of the information and disclosures required for annual financial statements. These financial statements should be read in conjunction with the financial statements and related footnotes for the year ended February 28, 2007 included in the Form 10-KSB for the year then ended.

In the opinion of the Company's management, all adjustments (consisting of normal recurring accruals) necessary to present fairly the Company's financial position as of November 30, 2007 and the results of operations and cash flows

for the nine-month period ended November 30, 2007 and 2006 have been included.

The results of operations for the three-month period ended November 30, 2007, are not necessarily indicative of the results to be expected for the full year. For further information, refer to the financial statements and footnotes thereto included in the Company's Form 10-KSB as filed with the Securities and Exchange Commission for the year ended February 28, 2007.

STOCKHOLDERS' EQUITY/NOTES PAYABLE

In connection with the Company's notes, the Company is obligated to issue four shares of its common stock each year for each dollar of principal borrowed. As of November 30, 2007 the Company is obligated to issue an additional 1,771,000 shares for previously executed note agreements. Such shares have been considered as issued for purposes of financial reporting.

RELATED PARTY LOANS

The President of the Company has advanced the Company \$100,000 under a demand loan which bears interest at the rate of 8%. This note has been approved by the Board of Directors. The President has agreed to extend the maturity date to March 30, 2009. Additionally, included in current liabilities are notes payable to related parties of \$88,036. Included in this amount is \$66,036 to the President of the Company and \$2,000 to the former Controller. The \$66,036 to the President represents short-term advances that are secured by certain customer accounts receivable. The \$2,000 to the former controller is currently past due and bears interest at the rate of 2% over prime.

During the third quarter a member of the Board of Directors loaned the company \$20,000 to make certain leasehold improvements. The loan bears interest at 6% simple interest and is unsecured.

STOCK OPTIONS

In June 2006, The Company approved the issuance of 4,360,000 shares to be awarded to employees and directors of the company. The company believes that such awards better align the intent of its employees and directors with those of its shareholders. The Options were granted with an exercise equal to the market price of the company's shares at the date of grant, which was \$.06 per share.

The fair market value of each option awarded is estimated on the date of grant using the Black Scholes Option Model that uses the assumptions noted in the following table. The factors utilized in the calculator of the fair market value of the option estimated to be \$37,518 is as follows:

6

Option Price	\$ 0.06
Share Price at date of Grant	\$ 0.06
Volatility	75%
Risk free interest rate	3.75%

A summary of options activity under the plan at November 30, 2007 is presented below:

	WEIGHTED WEIGHTED AVERAGE AVERAGE EXERCISED SHARES	WEIGHTED AVERAGE REMAINING CONTRACTUAL PRICE	WEIGHTED AVERAGE REMAINING CONTRACTUAL TERM	
Balance February 28, 2007	-	-	-	
Grant June 2007	4,360,000	0.06	3.5	
Balance Outstanding November 30, 2007	4,360,000	0.06	3.5	
Exercisable at November 30, 2007	1,690,000	0.06	3.5	

At November 30, 2007, there was \$59,274 of unrecognized compensation cost related to non-vested share based compensation agreements granted under the plan. The cost is expected to be recognized over the weighted average period of 5.5 years. The total fair market value of the shares vested during the years ending

February 28, 2008, 2009, 2010 and 2011 is \$13,172, \$19,758, \$19,758 and \$6,586.

PART I ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-QSB contains certain "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to us that are based on the beliefs of the management, as well as assumptions made by and information currently available. Our actual results may vary materially from the forward-looking statements made in this report due to important factors such as, recent operating losses, uncertainties associated with future operating results, unpredictability related to Food and Drug Administration regulations, introduction of competitive products, limited liquidity, reimbursement related risks, government regulation of the home health care industry, success of the research and development effort, market acceptance of FREEDOM60(R), availability of sufficient capital to continue operations and dependence on key personnel. When used in this report, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect current views with respect to future events based on currently available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. These statements involve risks and uncertainties with respect to the ability to raise capital to develop and market new products, acceptance in the market place of new and existing products, ability to penetrate new markets, our success in enforcing and obtaining patents, obtaining required Government approvals and attracting and maintaining key personnel that could cause the actual results to differ materially. Repro-Med does not undertake any obligation to release publicly any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

7

THREE MONTHS ENDED NOVEMBER 30 2007 VS. 2006

Sales of the FREEDOM60(R) Syringe Infusion System, related accessories and repairs have become our company's lead product representing 60% of the company's total sales this quarter as compared to 42% for the quarter ended November 30, 2006. Freedom60 sales experienced an overall increase of 97.4% from \$196,900 to \$388,723 in the third quarter ending November 30, 2007 as compared to the same period in 2006. This increase is primarily due to increased sales for the subcutaneous immune globulin (SCIG) market, which was significantly influenced by a Medicare clarification guidance document specifying the Freedom60 for reimbursement for use with SCIG. Additionally with the exposure of many new providers using the Freedom60, an increase in use for antibiotics also occurred.

During the quarter ended November 30, 2007 sales of the RES-Q-VAC(R) and related accessories increased domestically by 46.3% and declined internationally by 34.1% which netted a slight decrease overall of 6.0% from \$216,326 to \$203,280. These variations appear to be caused by normal fluctuations in ordering patterns with domestic and international sales cycles frequently offsetting during different quarters (See the Nine Months Ended Discussion).

Company sales of non-core products (Gyneco, Restore, and OEM lines), which at the end of the current quarter amounted to less than 5% of total sales and declined from \$46,903 to \$30,457 during the quarter ended November 30, 2007.

Total sales increased by 35.6% (\$162,888) from \$457,991 to \$620,879 for the three-month period ending November 30, 2007.

Net Income/(Loss) from operations shows a profit of \$80,807 for the three-months ending November 30, 2007 as compared to a profit of \$25,315 for the same quarter in 2006 and represents a total improvement of \$55,492 quarter over quarter.

Net profit for the Quarter was \$61,359, which includes \$4,750 in stock based compensation for financing cost, as compared to the previous quarter loss of \$67,695, which included stock based compensation for financing cost of \$88,090.

This is due to the stock based compensation for financing cost for 2007 being recorded in the first quarter of 2007 versus being recorded in the second and third quarters of 2006.

Gross Profit increased to 64% from 56.4% last year for the same period. This is a result of errors in pricing being recorded to the scrap account; which is consolidated in to Cost of Good Sold, and being reclassified in the third quarter of 2006. When gross profit is reviewed with typical scraping for the quarter the gross profit would have remained consistent with the current quarter.

Selling, General and Administrative Expense (SG&A) increased \$83,893 from \$205,094 to \$288,987 quarter over quarter 2007 vs. 2006, which included increased expenses related to our business expansion and included among others, an increase of \$20,477 in convention and trade show related expense associated to the MEDICA Trade show attended in November 2007, additional banking fees, office expenses, increased recruiting costs and the fair value of stock option aggregating \$37,500. Research and Development decreased \$1,339 as a result of increased concentration in the generating sales.

Interest expense decreased slightly \$793 to \$14,698 from \$15,491.

8

NINE MONTHS ENDED NOVEMBER 30 2007 VS. 2006

Total sales increased by 32.95% (\$402,518) from \$1,221,724 to \$1,624,242 for the nine-month period ending November 30, 2007.

Net Income/(Loss) from operations shows a profit of \$54,107 for the nine-months ending November 30, 2007 as compared to a loss of \$72,721 for the same nine-months in 2006 and represents a total improvement of \$126,827.

Net (Loss) for the nine-months ending was \$65,791, which includes \$75,840 in stock based compensation for financing cost and \$37,518 of employee and director stock options recorded as fair market value, as compared to the previous quarter loss of \$284,110, which included stock based compensation for financing cost of \$159,390. This is due to the stock based compensation for financing cost for 2007 being recorded in the first quarter of 2007 versus being recorded in the second and third quarters of 2006 as well as higher interest expense.

Sales of the FREEDOM60(R) Syringe Infusion System, related accessories and repairs have become our company's lead product representing 52% of the company's total sales for the nine-months ending November 30, 2007 as compared to 40% for the period ended November 2006 with total sales, domestic and international, increasing by 83%. The performance from this period resulted from a management shift in sales strategy which included eliminating outside consulting and in-house sales personnel who were ineffective in driving any new revenues and relying instead on our in house staff. During the past year we decided to focus the majority of our efforts in the Freedom60 line, specifically towards the subcutaneous immune globulin (SCIG) market. We made decisions to directly support clinical trials by providing 42 Freedom60 pumps at our sole expense into a phase IV clinical trial. We attended fourteen SCIG nursing education programs. This has allowed us to meet hundreds of nurses all over the country who administer to the needs of this market. We applied for better reimbursement from Medicare for the Freedom60. Due to our direct efforts, reimbursement was increased twenty fold and subsequently resulted in Medicare issuing a letter of clarification stating the Freedom60 as the only pump approved for SCIG reimbursement. Lastly, we diligently called on, in-serviced and sold virtually every major SCIG provider in the country. We anticipate these sales to continue to increase as the SCIG market continues to develop and as we work on new enhancements to the Freedom60 that we believe will expand this market even further. In addition, many of the SCIG users will see benefit in using the Freedom60 system for other uses, such as antibiotics, chemotherapeutics and pain medications

Sales of the RES-Q-VAC(R) increased overall by 6.1% from \$556,802 to \$590,823 with the international sales increasing by 5.4% from \$297,024 to \$313,010 and the domestic increasing by 6.9% from \$259,778 to \$277,813 for the nine-months ended November 30,2007 vs. nine-months ended November 30, 2006. The RES-Q-VAC sales occur in long sales cycles making short term trend analysis problematic. International sales cycles appear to run in approximately 18 month cycles.

Gross Profit increased slightly from 59.43% to 62.01% of net sales 2007. This is a result of errors in pricing being recorded to the scrap account; which is consolidated in to Cost of Good Sold, and being reclassified in the third quarter of 2006. When gross profit is reviewed with typical scrapping for the quarter the gross profit would have remained consistent with the current quarter.

Selling, General and Administrative Expense (SG&A) increased 21.83% from \$715,205 in 2006 to \$871,356 in 2007. This is increase is directly related to increases in trade show expenses, product liability insurance, recruiting expense, temporary help, the legal agreement and fees associated with a mediation agreement and the fair value of stock options aggregating \$37,500.

9

Research and development expenses increased minimally by \$3,141 from 2006 to 2007.

Depreciation and amortization expense decreased by \$3,668 from 2006 to 2007, as a result of equipment reaching the end of it depreciable life and not being fully replaced by equivalent capital investments.

Interest expense has decreased \$7,483 from 2006 to 2007 as a result of paying off high interest notes to the bank.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity has improved due to increased sales resulting in positive cash flow for the past two quarters. The additional resource's have been applied to a decrease in accounts payable which include vendors and selected debts, increases in prepaid debts, and a slight increase in inventory.

We continue to seek funds to enhance our marketing efforts substantially and for other corporate purposes, although there is no assurance that such funding can be obtained, or obtained at terms acceptable to us. Substantial attention has been directed into our marketing during the past year which produced an increase in new RES-Q-VAC(R) customers and significant increases in new FREEDOM60(R) users. Our marketing focus on the Freedom60 will continue and is expected to maintain the trend of increasing sales for that product line.

We believe we will continue to enhance our customer base for our products. With the current capital and cash flow, and if sales continue to meet the Company's targets, which we expect but cannot assure, we will have sufficient resources to meet our obligations for the next twelve months. However, if the current trend does not continue, and if new funding does not become available, then our viability could be in question. We remain cautiously optimistic that, at a minimum, sales will continue to increase and meet our expectations and needs for the coming year.

FREEDOM60(R)

The FREEDOM60(R) Syringe Infusion Pump is designed for ambulatory medication infusions. Ambulatory infusion pumps are most prevalent in the home care market. Other potential applications for the FREEDOM60(R) are pain control, the infusion of specialized drugs such as IgG, and chemotherapy. The home infusion therapy market is comprised of approximately 4,500 sites of service, including local and national organizations, hospital-affiliated organizations, and national home infusion organizations, and produces approximately \$4.5 Billion in revenue annually (Ref: www.nhianet.org). With insurance reimbursement in a severe decline, there is a tremendous need for a low-cost, effective alternative to electronic and expensive disposable IV administration devices for the home care and nursing home market.

The FREEDOM60(R) provides a high-quality delivery to the patient at costs similar to gravity and is targeted for the home health care industry, patient emergency transportation, and for any time a low-cost infusion is required.

For the home care patient, FREEDOM60(R) is an easy-to-use lightweight mechanical pump using a 60cc syringe, completely portable, cost effective and maintenance free, with no batteries to replace and no cumbersome IV pole. For the infusion

professional, FREEDOM60(R) delivers precise infusion rates and uniform flow profiles providing consistent transfer of medication. A Form 510(k) Pre-market Notification for initial design of the FREEDOM60(R) as a Class II device was approved by the FDA in August 1994.

10

The Company also designed and manufactured the FREEDOM60(R)-FM, an enhanced version of the FREEDOM60(R) which contains an electronic flow monitor system that provides occlusion and end of infusion alarm. This product is directed at nursing homes, hospitals and pediatric ambulatory applications where alarms are generally required for nursing acceptance. Nurses also appreciate being able to visualize the drug volume by reading the scale on the syringe.

We have expanded the use of the FREEDOM60(R) to cover most antibiotics including the widely used and somewhat difficult to administer vancomycin. We have also found a following for FREEDOM60(R) for use in treating thalissemia with the drug desferal. In Europe we found success in using the FREEDOM60(R) for pain control, specifically post-operative epidural pain administration. Our European market also uses the FREEDOM60(R) for chemotherapy.

The FREEDOM60(R) use for Primary Immune Deficiency by injecting immune globulin (IgG) under the skin as a subcutaneous administration has seen increased usage over the past year. This method has provided patients with vastly improved quality of life with much fewer unpleasant side effects over the traditional intravenous route. The FREEDOM60(R) is an ideal system for this administration since the patient is able to self-medicate at home, the pump is easily configured for this application, and the FREEDOM60(R) is the lowest cost infusion system available in a heavily cost constrained market. Also due to its safe, limited and controlled pressure system, the Freedom60 adjusts automatically to the patient's needs providing a reliable and comfortable administration for these patients.

Repro-Med Systems' objective is to build a product franchise with FREEDOM60(R) and the sale of patented disposable tubing sets. FREEDOM60(R) uses rate-controlled tubing with standard slide clamp and luer-lock connector on the patient end. Our patented syringe disc connector insures that only the Company's FREEDOM60(R) tubing sets will function with the pump. Non-conforming tubing sets, without the patented disc connector, are ejected from the pump to prevent the danger of an overdose or runaway pump from injuring the patient.

THE MARKET FOR INFUSION PUMPS & DISPOSABLES

The ambulatory market has been rapidly changing due to reimbursement issues. Insurance reimbursement has drastically reduced the market share of high-end electronic type delivery systems as well as high-cost disposable non-electric devices, providing an opportunity for the FREEDOM60(R). The Freedom60 was reclassified by the Centers for Medicare and Medicaid on May 21, 2007 for use under code E0779 which increases the reimbursement for the Freedom60 for all billable syringe pump applications approved by Medicare.

We believe market pressures have moved patients to low-cost gravity system or IV push where the drug is pushed into the vein directly from a syringe. This is a low-cost option but has been associated with complications and considered by many to be a high-risk procedure. Thus, the overall trend has been towards syringe pumps due to the low-cost of disposables. FREEDOM60(R)-FM addresses the largest market segments with the lowest cost alarm syringe pump system.

In order to receive more favorable Medicare reimbursement for our FREEDOM60(R) Syringe Infusion System, we had submitted a formal request for a HCPCS coding verification with the Statistical Analysis Durable Medical Equipment Regional Carrier (SADMERC). On May 21, 2007 we received a notification from CMS (Centers for Medicare & Medicaid Services) that the Freedom 60(R) had been re-reviewed for Medicare billing. It was the determination that the Medicare HCPCS code(s) to bill the four Durable Medical Regional Carriers (DMERCs) should be: E0779 Ambulatory infusion pump, mechanical, reusable, for infusion 8 hours or greater. The new coding provides for a substantial increase in reimbursement for providers using an infusion pump for authorized users under Part B of Medicare.

11

Current approved uses under Medicare include among others, subcutaneous immune globulin, antivirals, antifungals, and chemotherapeutics. In June 2007 CMS

issued a clarification that the Freedom 60(R) Syringe Infusion Pump is the only allowable pump to be billed with subcutaneous immune globulin under HCPCS code E0779.

RES-Q-VAC(R)

- -----

The RES-Q-VAC(R) Emergency Airway Suction System, is a lightweight, portable, hand-operated suction device that removes fluids from a patient's airway by attaching the RES-Q-VAC(R) pump to various proprietary sterile and non-sterile single-use catheters sized for adult and pediatric suctioning. The one-hand operation makes it extremely effective and the product is generally found in emergency vehicles, hospitals and wherever portable aspiration is a necessity, including backup support for powered suction systems. The disposable features of the RES-Q-VAC(R) reduce the risk of contaminating the health professional from HIV or SARS when suctioning a patient or during post treatment cleanup. All of the parts that connect to the pump are disposable.

We recently introduced a new version of the RES-Q-VAC with the addition of a portable LED white light, which attaches to the canister assembly. The light is fully malleable and can direct light during operations when lighting is poor or at night. We have begun marketing the new system with a national master distributor and will introduce the new product to the international community during the second quarter.

A critical component and advantage of the RES-Q-VAC(R) is the Full Stop Protection(R), (FSP(R)) a recently patented filtering system that both prevents leakage and over-flow of the aspirated fluids, even at full capacity, and traps all air and fluid borne pathogens and potentially infectious materials within the sealable container. This protects users from potential exposure to disease and contamination. The Full Stop Protection(R) meets the requirement of the Occupational Safety and Health Administration as described below. The Company has received a letter from OSHA confirming that the RES-Q-VAC(R) with the Full Stop Protection(R) falls under the engineering controls of the Blood borne Pathogen regulation and that the Products use would fulfill the regulatory requirements.

We have also added new connectors to our pediatric catheters, which allow them to connect directly to the adult containers with FSP(R). These connectors allow pediatric suctioning with the benefit of the Full Stop Protection(R) device as well as with sterile catheters. Many infants are born with contagious diseases and the new system eliminates this concern among paramedics during an emergency delivery.

A critical advantage of our RES-Q-VAC(R) airway suction system is versatility. With the addition of Full Stop Protection(R), we created specific custom RES-Q-VAC(R) kits for various vertical markets:

Emergency Medicine - we make several special kits for emergency use, which contain all the catheters necessary to treat adults as well as infants or children. These first responder kits are generally non-sterile. We also have special attachments available for the advanced paramedic to treat patients who are intubated.

Respiratory - in-home care, long term care, situations requiring frequent suctioning such as cystic fibrosis patients, patients with swallowing disorders, elderly, patients on ventilators and with tracheostomies all benefit from the portability, cost and performance of the RES-Q-VAC(R). In hospitals, the RES-Q-VAC(R) provides emergency back up due to power loss or breakdown of the wall suction system.

Hospital Use - for crash carts, the emergency room, patients in isolation, moving patients throughout the hospital (e.g., from ICU to Radiology) and backup for respiratory, RES-Q-VAC(R) is available sterile with Full Stop Protection(R) for the ultimate in performance and to meet all the OSHA regulations and CDC guidelines for use in treating patients in isolation, and in any location. Hospitals are required under the EMTALA regulations to provide emergency treatments to patients anywhere in the primary facility and up to 250 yards away. The RES-Q-VAC insures full compliance with these regulations and helps minimize unfavorable outcomes and potential lawsuits there from. We provide special hospital kits, which are fully stocked to meet all hospital applications

for both adult and pediatric.

Nursing homes, hospice, sub-acute - we provide special configurations for dining areas, portable suctioning for outside events and travel. Chronic suction can be accommodated with RES-Q-VAC(R), which can be left by the bedside for rapid use during critical times.

Dental applications - we offer a version of the RES-Q-VAC(R), called DENTAL-EVAC(R) which addresses the needs of oral surgeons for emergency back up suction during a procedure. DENTAL-EVAC(R) is supplied with the dental suction attachments such as saliva ejector and high volume evacuator.

Military Applications -Due to its lightweight, portability, and rapid deployment, we believe that the RES-Q-VAC(R) is ideal for any military situation. In addition, rapid, aggressive, and repeated suctioning best treats exposure to chemical weapons of mass destruction such as Sarin. We believe that the RES-Q-VAC(R)'s compact size, powerful pump, and full protection of the user from any contamination, gives us a competitive edge in this market.

RES-Q-VAC(R) is sold domestically and internationally by emergency medical device distributors. These distributors generally sell to the end user and advertise these products in relevant publications and in their catalogs.

TRADE SHOWS

- - - - -

We continue to support our products at several trade shows. During the months of November attend the MEDICA Show in Dusseldorf, Germany.

PART II - OTHER INFORMATION

- - - - -

ITEM 1. LEGAL PROCEEDINGS

- - - - -

We are, from time to time, subject to claims and suits arising in the ordinary course of business, including claims for damages for personal injuries, breach of management contracts and employment related claims.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

- - - - -

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

- - - - -

None

13

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

- - - - -

No matters were submitted to a vote of security holders of the Company during the quarter ended November 30, 2007.

ITEM 5. OTHER INFORMATION

- - - - -

None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

- - - - -

(a) EXHIBITS

31.1 Certification of Chief Executive Officer and Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act 2002

32.1 Certification of Chief Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002

(b) REPORTS

ITEM 7. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer, or CEO, acting as Chief Financial Officer, or CFO, and the Chief Operating Officer, or COO, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of November 30, 2007. Based on that evaluation, our management, including our CEO/CFO and COO, concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and is accumulated and communicated to our management, including our CEO/CFO and COO, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the three months ended November 30, 2007 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

14

SIGNATURES

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934 the Registrant has duly caused this report to be signed on its behalf by the undersigned; thereunto duly authorized.

REPRO-MED SYSTEMS, INC.

/s/ Andrew I. Sealfon

March 17, 2008

Andrew I. Sealfon, President, Treasurer,
Chairman of the Board, Director, and
Chief Executive Officer

15

EXHIBIT 31.1

CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrew I. Sealfon, certify that:

1. I have reviewed Amendment No. 1 to the Form 10-QSB of Repro-Med Systems, Inc. (the "Report");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4. The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c) disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and

5. The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: March 17, 2008

/s/ Andrew I. Sealfon

Andrew I. Sealfon, President, Treasurer,
Chairman of the Board, Director, Chief Executive Officer
and Principal Financial Officer

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTIONS 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repro-Med Systems, Inc., on Form 10-QSB/A Amendment No. 1 for the period ending November 30, 2007 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Andrew Sealfon, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Andrew I. Sealfon

Andrew I. Sealfon, President, Treasurer,
Chairman of the Board, Director, Chief Executive Officer
and Principal Financial Officer

March 17, 2008